20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
CYTOBALANCE analyzes the level of pro-inflammatory cytokines to assess chronic inflammation, a well-known promoter of genomic instability. It is part of the HELIXAFE prevention model, which also includes the analysis of genomic instability, gut dysbiosis, and immune system imbalance. The link between inflammation and colorectal cancer has been suggested by epidemiological and experimental data and confirmed by anti-inflammatory therapies that show efficacy in cancer prevention and treatment. Chronic inflammation is induced by biological, chemical, and physical factors; the longer it persists, the higher the risk of cancer. This sustained inflammatory/oxidative environment leads to a vicious cycle, which can damage healthy neighboring epithelial and stromal cells and can lead to carcinogenesis in the long run
